Chronic Kidney Disease-Mineral and Bone Disorder:
Translating Evidence Into Practice

Salient changes in the new CKD-MBD 2017 KDIGO guidelines:
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
Link: http://www.kidney-international.org/article/S0085-2538(17)30249-1/fulltext

Understanding the new findings in the pathogenesis of CKD-MBD:

Approaches to decreasing Npt2b expression:
Link: http://www.ingentaconnect.com/content/wk/mnh/2016/00000025/00000004/art00005?crawler=true

Review of IV calcimimetic etelcalcetide and oral calcimimetic cinacalcet on serum parathyroid hormone (PTH) concentrations in patients receiving hemodialysis:
Link: http://jamanetwork.com/journals/jama/article-abstract/2596294

Review of IV calcimimetic etelcalcetide compared with placebo on serum parathyroid hormone (PTH) concentrations in patients receiving hemodialysis:
Link: http://jamanetwork.com/journals/jama/article-abstract/2596293

Results of meta-analysis of sevelamer and its effects on cardiovascular calcification in patients with CKD:
Link: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0133938
Review of ferric citrate as an option among phosphate binders:
**Link:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868355/

The effects of tenapanor on serum phosphate concentration in patients with hyperphosphatemia receiving hemodialysis:
**Link:** http://jasn.asnjournals.org/content/early/2017/02/02/ASN.2016080855.long

The effect of ER calcifediol:
**Link:** https://www.karger.com/Article/Abstract/450766